Balixafortide TFA

POL6326 TFA

Balixafortide TFA

B658810-5mg

5mg

Moligand™

≥98%

避光,-20°C储存,充氩

超低温冰袋运输

对光线敏感；对湿度敏感

Balixafortide TFA (POL6326 TFA) 是一种有效的，选择性的，耐受性好的肽类 CXCR4 拮抗剂，其 IC50 小于 10 nM。Balixafortide TFA 对 CXCR4 的选择性比包括 CXCR7 在内的许多受体高出 1000 倍。Balixafortide TFA 以 IC50 序列： Cyclo(Ala-Cys-Ser-Ala-{D-Pro}-{Dab}-Arg-Tyr-Cys-Tyr-Gln-Lys-{D-Pro}-Pro-Tyr-His) (Disulfide bridge: Cys2-Cys9) Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC 50 Appearance:Solid IC50& Target:CXCR4 In Vitro:Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Namalwa (IC 50 In Vivo:Balixafortide is optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability. MCE has not independently confirmed the accuracy of the Biological Activity:Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC 50

1051366-32-5(free base)

C84H118N24O21S2(free base)

1864.11(free base) g/mol

H2O : 100 mg/mL (50.55 mM; Need ultrasonic) DMSO : 100 mg/mL (50.55 mM; Need ultrasonic)